Prodrugs:: design and clinical applications

被引:1204
作者
Rautio, Jarkko [1 ]
Kumpulainen, Hanna [1 ]
Heimbach, Tycho [2 ]
Oliyai, Reza [3 ]
Oh, Dooman [4 ]
Jarvinen, Tomi [1 ]
Savolainen, Jouko [5 ]
机构
[1] Univ Kuopio, Dept Pharmaceut Chem, FI-70211 Kuopio, Finland
[2] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[3] Gilead Sci Inc, Foster City, CA 94404 USA
[4] Amgen Inc, Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[5] Fennopharma Ltd, FI-70210 Kuopio, Finland
关键词
D O I
10.1038/nrd2468
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/ or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.
引用
收藏
页码:255 / 270
页数:16
相关论文
共 190 条
  • [41] Prediction of gastro-intestinal absorption using multivariate adaptive regression splines
    Deconinck, E
    Xu, QS
    Put, R
    Coomans, D
    Massart, DL
    Heyden, YV
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (05) : 1021 - 1030
  • [42] Doucette K E, 2001, Expert Opin Pharmacother, V2, P1671
  • [43] COMPARATIVE DISPOSITION OF SULINDAC AND METABOLITES IN 5 SPECIES
    DUGGAN, DE
    HOOKE, KF
    NOLL, RM
    HUCKER, HB
    VANARMAN, CG
    [J]. BIOCHEMICAL PHARMACOLOGY, 1978, 27 (19) : 2311 - 2320
  • [44] DUGGAN DE, 1977, CLIN PHARMACOL THER, V21, P326
  • [45] ECOBICHON DJ, 1972, RES COMMUN CHEM PATH, V3, P629
  • [46] PHARMACOKINETICS OF AMPICILLIN AND ITS PRODRUGS BACAMPICILLIN AND PIVAMPICILLIN IN MAN
    EHRNEBO, M
    NILSSON, SO
    BOREUS, LO
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1979, 7 (05): : 429 - 451
  • [47] Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood
    Eisenberg, EJ
    He, GX
    Lee, WA
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) : 1091 - 1098
  • [48] Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans
    Eriksson, UG
    Bredberg, U
    Hoffmann, KJ
    Thuresson, A
    Gabrielsson, M
    Ericsson, H
    Ahnoff, M
    Gislén, K
    Fager, G
    Gustafsson, D
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) : 294 - 305
  • [49] Erion MD, 2006, CURR OPIN INVESTIG D, V7, P109
  • [50] Liver-targeted drug delivery using HepDirect1 prodrugs
    Erion, MD
    van Poelje, PD
    MacKenna, DA
    Colby, TJ
    Montag, AC
    Fujitaki, JM
    Linemeyer, DL
    Bullough, DA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (02) : 554 - 560